The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) and keeping the price target at $46.00. Discover outperforming stocks and ...
In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price target of $38.00. Discover outperforming stocks ...
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback